NLA, EAS Recast Statin Care With Age-70 Trigger and CAC 1,000 Imaging Threshold
Updated
Updated · Pharmacy Times · Jun 13
NLA, EAS Recast Statin Care With Age-70 Trigger and CAC 1,000 Imaging Threshold
1 articles · Updated · Pharmacy Times · Jun 13
Summary
Chicago session speakers said cardiovascular prevention is shifting from biomarker-led screening to image-based staging of actual plaque burden, with pharmacists cast as key guides for treatment decisions.
2025 ESC/EAS dyslipidemia updates now tie statin initiation to SCORE2 for under-70s and SCORE-OP for ages 70 to 90, while treating older age as a stronger reason to start therapy because absolute ASCVD risk rises sharply after 70.
Regional risk also changes thresholds: in very-high-risk areas, statins should be considered for women from 45 and men from 40, versus women over 70 and men over 60 in low-risk countries such as Denmark.
Lipoprotein(a) testing was framed as a once-in-a-lifetime measure for every adult, with 50 mg/dL marking significant risk and phase 3 drugs including pelacarsen targeting about 80% reductions from late 2026.
Imaging is gaining guideline weight: 2026 ACC guidance gives coronary calcium scoring a Class 1 role for borderline or intermediate-risk patients, and a CAC score above 1,000 signals extremely high risk with LDL-C goals below 55 mg/dL.
With potent Lp(a) drugs arriving soon, are we ready for the next blockbuster pricing debate?
As imaging replaces risk scores, will advanced heart care become a luxury for the wealthy?
Does staging heart disease like cancer risk over-medicalizing aging and creating unnecessary patient anxiety?
The 2026 Statin Guidelines: Aggressive LDL-C Targets, Precision Risk Assessment, and the Future of Cardiovascular Prevention
Overview
The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, approved by leading medical associations and published in March 2026, marks a major shift in cardiovascular prevention. With an estimated 1 in 4 U.S. adults having high LDL cholesterol—a key risk factor for heart attack and stroke—the guidelines stress that lowering LDL as much as possible is crucial. For patients at very high risk, the new target is an LDL-C level below 55 mg/dL. These changes are designed to improve public health outcomes by promoting more aggressive and personalized cholesterol management.